Fingolimod for Type 2 Diabetes Mellitus

Inclusion criteria

• Age: 18-70 years old;
• clinically diagnosed type 2 diabetes.
• Glycosylated hemoglobin: 6.5% - 9.5%;
• No drug treatment or only one oral hypoglycemic drug within 6 months;
• Fasting blood glucose: < 13.9mmol/l for those without medication, or < 13.3mmol/l for those with medication;
• if the antidiabetic drugs are taken, the dosage and the drug must be stable in the past 3 months.
• Body mass index (BMI) ≤ 45 kg / m2;
• Sign informed consent

Exclusion criteria

• patients with type 1 diabetes;
• diabetic complications (ketoacidosis, hypertonic state, lactic acidosis).
• Allergic to the study drug;
• Abnormal liver and kidney function (transaminase greater than 2.5 times the upper limit of normal value; creatinine greater than 133umol / L);
• Complicated with other serious organ diseases;
• Recent disease history (within the past 6 months): myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or class III / IV heart failure;
• Presence or history of mobitz type II second or third degree AV block or sick sinus syndrome, unless the patient has a pacemaker;
• Baseline QT interval extension (male > 450ms or female > 460ms);
• Treatment with class IA or class III antiarrhythmic drugs;
• Patients with systemic infection (including but not limited to bacteria, fungi, viruses, etc.);
• Participating in other clinical trials within 3 months;
• Other circumstances that the investigator considers unsuitable for participating in this clinical study.